The PROSPECT-Lung trial (CTIU2317-A082304-S2402) is presented as a pragmatic clinical trial design intended to improve cancer trial efficiency without compromising scientific rigor. The trial focuses on patients with resectable non-small cell lung cancer and compares perioperative versus adjuvant systemic therapy. The described approach emphasizes simplified eligibility criteria, a streamlined protocol, and reduced data-collection demands to address common sources of inefficiency in traditional trials, such as extensive data requirements, restrictive entry criteria, lengthy protocols, staffing shortages, and operational burden. By adopting pragmatic features, the design aims to facilitate faster accrual and lower operational costs while preserving methodological integrity. The description positions PROSPECT-Lung as a potential model for aligning pragmatic trial elements with rigorous research standards in oncology. The source notes uncertainty regarding specific outcomes, statistical methodologies, or enrollment targets beyond the stated aims of efficiency and feasibility. If more detailed results or formal comparative analyses are available, they are not provided in the quoted material.
Clinical trial designs marked by extensive data collection, restrictive eligibility, and lengthy protocols create inefficiencies, increase costs, and hinder accrual. These are further compounded by staffing shortages and operational burdens. By incorporating pragmatic features, including simplified eligibility criteria, streamlined protocol, and data collection, the PROSPECT-Lung trial, CTIU2317-A082304-S2402 Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable NSCLC, paves the way forward as a model for enhancing clinical trial efficiency and feasibility, while maintaining scientific rigor.